Materials technology in drug eluting balloons: Current and future perspectives.

The coating material technology is important for the delivery of anti-proliferative drugs from the surface of drug-eluting balloons (DEBs), which are emerging as alternatives to drug-eluting stents (DES) in the field of interventional cardiology. Currently, several shortcomings limit their competition with DES, including low drug transfer efficiency to the arterial tissues and undesirable particulate generation from the coating matrix. In this review, we provide a survey of the materials used in existing DEBs, and discussed the mechanisms of actions of both the drugs and coating materials. The type of drug and the influence of the coating material characteristics on the drug uptake, distribution and retention in arterial tissues are described. We also summarize the novel coating excipients under development and provide our perspective on the possible use of nano-scale carriers to address the shortcomings of current coating technology. The scope of this review includes only materials that have been approved for biomedical applications or are generally recognized as safe (GRAS) for drug delivery.

[1]  R. Virmani,et al.  Pathologic evaluation of a spherical polyvinyl alcohol embolic agent in a porcine renal model. , 2003, Journal of vascular and interventional radiology : JVIR.

[2]  P. Stella,et al.  Drug-eluting balloons and bifurcations, a new future? , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[3]  W. Gasper,et al.  Adventitial Nab-Rapamycin Injection Reduces Porcine Femoral Artery Luminal Stenosis Induced by Balloon Angioplasty via Inhibition of Medial Proliferation and Adventitial Inflammation , 2012, Circulation. Cardiovascular interventions.

[4]  Jin Sun,et al.  Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. , 2009, Recent patents on anti-cancer drug discovery.

[5]  J. Granada,et al.  Tissue uptake, distribution, and healing response after delivery of paclitaxel via second-generation iopromide-based balloon coating: a comparison with the first-generation technology in the iliofemoral porcine model. , 2013, JACC. Cardiovascular interventions.

[6]  E J Topol,et al.  Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. , 1996, Circulation.

[7]  A. Tzafriri,et al.  Enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[8]  J. Cinca,et al.  UPDATE ON DRUG-ELUTING BALLOONS FOR PERCUTANEOUS CORONARY INTERVENTIONS , 2013 .

[9]  B. Cremers,et al.  Paclitaxel-coated balloons - Survey of preclinical data. , 2010, Minerva cardioangiologica.

[10]  Ralf Degenhardt,et al.  Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis , 2009, Circulation.

[11]  E. Hannan,et al.  Safety and Efficacy of Drug-Eluting and Bare Metal Stents: Comprehensive Meta-Analysis of Randomized Trials and Observational Studies , 2009, Circulation.

[12]  R. Kuntz,et al.  Zotarolimus (ABT-578) eluting stents. , 2006, Advanced drug delivery reviews.

[13]  P. Barragan,et al.  SeQuentPlease World Wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. , 2012, Journal of the American College of Cardiology.

[14]  T. Lüscher,et al.  Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. , 2010, European heart journal.

[15]  W. Weitschies,et al.  In Vitro Determination of Drug Transfer from Drug-Coated Balloons , 2013, PloS one.

[16]  A. Domb,et al.  Crystalline coating of rapamycin onto a stent: process development and characterization. , 2013, International journal of pharmaceutics.

[17]  James Margolis,et al.  Systemic Nanoparticle Paclitaxel (nab‐Paclitaxel) for In‐stent Restenosis I (SNAPIST‐I): A First‐in‐Human Safety and Dose‐finding Study , 2007, Clinical cardiology.

[18]  M. Gyöngyösi,et al.  Attainment of local drug delivery with paclitaxel-eluting balloon in porcine coronary arteries , 2008, Coronary artery disease.

[19]  P. Cullis,et al.  Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.

[20]  Juan F Granada,et al.  Drug-coated balloons for the prevention of vascular restenosis. , 2010, Circulation.

[21]  D. Scheinert,et al.  The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. , 2014, JACC. Cardiovascular interventions.

[22]  U. Kragl,et al.  Correlating Coating Characteristics with the Performance of Drug-Coated Balloons – A Comparative In Vitro Investigation of Own Established Hydrogel- and Ionic Liquid-Based Coating Matrices , 2015, PloS one.

[23]  Chong-Kook Kim,et al.  Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. , 2007, Biomaterials.

[24]  Wei Wu,et al.  Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus , 2016, Drug delivery.

[25]  G. Haugstad,et al.  Characterization of Pebax angioplasty balloon surfaces with AFM, SEM, TEM, and SAXS. , 2016, Journal of biomedical materials research. Part B, Applied biomaterials.

[26]  Yingying Huang,et al.  Drug-eluting biostable and erodible stents. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[27]  A. Kastrati,et al.  Paclitaxel-Coated Versus Uncoated Balloon Angioplasty Reduces Target Lesion Revascularization in Patients With Femoropopliteal Arterial Disease: A Meta-Analysis of Randomized Trials , 2012, Circulation. Cardiovascular interventions.

[28]  Tyler Remund,et al.  Preparation, characterization, in vitro drug release, and cellular interactions of tailored paclitaxel releasing polyethylene oxide films for drug-coated balloons. , 2016, Acta biomaterialia.

[29]  M. Böhm,et al.  Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of Restenosis , 2004, Circulation.

[30]  Y. Rosen,et al.  Drug Delivery Systems for Vascular Disease Therapy , 2012 .

[31]  R. Langer,et al.  In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid–polymeric nanoparticles , 2011, Proceedings of the National Academy of Sciences.

[32]  R. Pakala,et al.  Drug-eluting balloon: the comeback kid? , 2009, Circulation. Cardiovascular interventions.

[33]  U. Christians,et al.  Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[34]  M. Joner,et al.  Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[35]  M. Leon,et al.  An update on the clinical use of drug-coated balloons in percutaneous coronary interventions , 2016, Expert opinion on drug delivery.

[36]  J. Laird,et al.  Drug-coated balloons for infrapopliteal disease: digging deep to understand the impact of a negative trial. , 2014, Journal of the American College of Cardiology.

[37]  N. Zhang,et al.  New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles , 2009, Drug delivery.

[38]  Masataka Nakano,et al.  Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug‐coated balloon in a swine femoral artery model , 2014, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[39]  T. Albrecht,et al.  Paclitaxel-Coated Balloons Reduce Restenosis After Femoro-Popliteal Angioplasty: Evidence From the Randomized PACIFIER Trial , 2012, Circulation. Cardiovascular interventions.

[40]  F. Vermassen,et al.  Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. , 2014, Journal of the American College of Cardiology.

[41]  U. Kragl,et al.  Usage of different vessel models in a flow-through cell: in vitro study of a novel coated balloon catheter , 2015 .

[42]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[43]  S. Sadeghian,et al.  Sirolimus-loaded stealth colloidal systems attenuate neointimal hyperplasia after balloon injury: a comparison of phospholipid micelles and liposomes. , 2013, International journal of pharmaceutics.

[44]  Q. Nguyen,et al.  Pervaporation of aqueous ester solutions through hydrophobic poly(ether-block-amide) copolymer membranes , 1998 .

[45]  M. Leon,et al.  Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing , 2014, Open Heart.

[46]  R. Virmani,et al.  Vascular Response to Zotarolimus-Coated Balloons in Injured Superficial Femoral Arteries of the Familial Hypercholesterolemic Swine , 2011, Circulation. Cardiovascular interventions.

[47]  K. Barth,et al.  Peripheral angioplasty balloon technology , 1993, CardioVascular and Interventional Radiology.

[48]  S. Spiliopoulos,et al.  Drug-eluting versus plain balloon angioplasty for the treatment of failing dialysis access: final results and cost-effectiveness analysis from a prospective randomized controlled trial (NCT01174472). , 2015, European journal of radiology.

[49]  L. Barbu-Tudoran,et al.  Deposition of nanoparticles in the arterial vessel by porous balloon catheters: Localization by confocal laser scanning microscopy and transmission electron microscopy , 2002, AAPS PharmSci.

[50]  M. Shibuya,et al.  Impact of Paclitaxel Dose on Tissue Pharmacokinetics and Vascular Healing: A Comparative Drug-Coated Balloon Study in the Familial Hypercholesterolemic Swine Model of Superficial Femoral In-Stent Restenosis. , 2015, JACC. Cardiovascular interventions.

[51]  S. Spiliopoulos,et al.  Paclitaxel-Coated Balloon Angioplasty vs. Plain Balloon Dilation for the Treatment of Failing Dialysis Access: 6-Month Interim Results From a Prospective Randomized Controlled Trial , 2012, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[52]  M. Joner,et al.  Drug-coated balloon therapy in coronary and peripheral artery disease , 2014, Nature Reviews Cardiology.

[53]  Mansoor M. Amiji,et al.  Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery , 2007, Pharmaceutical Research.

[54]  Tyler Remund,et al.  Dextran sulfate as a drug delivery platform for drug‐coated balloons: Preparation, characterization, in vitro drug elution, and smooth muscle cell response , 2015, Journal of biomedical materials research. Part B, Applied biomaterials.

[55]  Deepak L. Bhatt,et al.  Drug delivering technology for endovascular management of infrainguinal peripheral artery disease. , 2014, JACC. Cardiovascular interventions.

[56]  B. Dave,et al.  Basic Concepts and Clinical Outcomes of Drug-Eluting Balloons for Treatment of Coronary Artery Disease: An Overview. , 2017, Journal of clinical and diagnostic research : JCDR.

[57]  Dirk Mahnkopf,et al.  Dose Response to Paclitaxel-Coated Balloon Catheters in the Porcine Coronary Overstretch and Stent Implantation Model , 2011, Investigative radiology.

[58]  A. Tzafriri,et al.  Lesion complexity determines arterial drug distribution after local drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[59]  Liang Xie,et al.  The Potential Efficacy of R8-Modified Paclitaxel-Loaded Liposomes on Pulmonary Arterial Hypertension , 2013, Pharmaceutical Research.

[60]  A. Tzafriri,et al.  Mechanisms of Tissue Uptake and Retention in Zotarolimus-Coated Balloon Therapy , 2013, Circulation.

[61]  E. Edelman,et al.  Arterial paclitaxel distribution and deposition. , 2000, Circulation research.

[62]  Y. Ikada,et al.  Dynamic Wetting and Contact Angle Hysteresis of Polymer Surfaces Studied with the Modified Wilhelmy Balance Method , 1994 .

[63]  E. Edelman,et al.  Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Feng Liu,et al.  Understanding the structure and stability of paclitaxel nanocrystals. , 2010, International journal of pharmaceutics.

[65]  W. Weitschies,et al.  In vitro evaluation of paclitaxel coatings for delivery via drug-coated balloons. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[66]  J. Brachmann,et al.  A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. , 2012, Journal of the American College of Cardiology.